JUSH Jushi Holdings Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1909747 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.2%
TTM net income YoY15.7%
TTM EPS YoY15.2%
Revenue 3-yr CAGR-0.2%
Net income 3-yr CAGR—
Margins
Gross margin44.2%
Operating margin2.4%
Net margin-20.0%
FCF margin2.2%
EBITDA margin11.1%
Returns
ROE—
ROA-12.9%
ROIC (approx.)8.6%
Asset turnover0.65x
Leverage & solvency
Liabilities / assets136.3%
Debt / equity—
Current ratio0.79x
Interest coverage0.16x
Cash quality & payout
Operating cash flow / net income-0.34x
Accruals ratio-17.3%
Payout ratio—
Capex / revenue4.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $262.91M | $257.52M | $269.44M | $284.28M | $209.29M |
| Cost of revenue | $148.93M | $139.22M | $153.22M | $188.81M | $125.90M |
| Gross profit | $113.98M | $118.30M | $116.23M | $95.48M | $83.39M |
| SG&A expense | $109.13M | $107.01M | $110.47M | $156.17M | $112.81M |
| Operating income | $4.85M | $10.86M | -$2.82M | -$220.33M | -$35.77M |
| Interest expense | $41.30M | $37.98M | $37.06M | $45.73M | $30.85M |
| Income tax | $34.99M | $31.63M | $31.81M | $8.45M | $29.62M |
| Net income | -$68.59M | -$48.78M | -$65.10M | -$202.32M | $20.25M |
| EBITDA | $35.84M | $40.75M | $23.77M | -$193.84M | -$27.35M |
| EPS (basic) | -0.35 | -0.25 | -0.33 | -1.06 | 0.12 |
| EPS (diluted) | -0.35 | -0.25 | -0.33 | -1.44 | -0.42 |
| Weighted avg. shares (diluted) | 195.20M | 195.16M | 194.77M | 204.24M | 201.61M |
| Banking | |||||
| Net interest income | — | — | -$36.97M | -$45.59M | -$30.61M |
| Balance sheet | |||||
| Cash & equivalents | $24.05M | $21.35M | $31.30M | $27.15M | $94.96M |
| Receivables | $2.80M | $1.46M | $3.38M | $4.81M | $3.20M |
| Inventory | $34.61M | $36.14M | $33.59M | $35.09M | $43.32M |
| Current assets | $68.31M | $72.15M | $81.64M | $70.05M | $154.36M |
| PP&E, net | $143.32M | $144.06M | $159.27M | $177.75M | $137.28M |
| Goodwill | $30.91M | $30.91M | $30.91M | $38.24M | $45.83M |
| Intangibles | $92.20M | $100.47M | $95.97M | $100.08M | $192.47M |
| Total assets | $422.34M | $440.32M | $463.39M | $529.34M | $652.05M |
| Current liabilities | $66.19M | $68.89M | $162.46M | $107.63M | $83.93M |
| Short-term debt | $6.64M | $2.76M | $86.51M | $8.70M | $6.18M |
| Long-term debt | $199.19M | $183.45M | $126.04M | $180.56M | $119.80M |
| Total debt | $205.83M | $186.21M | $212.56M | $189.26M | $125.98M |
| Total liabilities | $537.69M | $490.56M | $471.01M | $483.45M | $471.07M |
| Shareholders' equity | -$115.34M | -$50.23M | -$6.23M | $47.28M | $182.37M |
| Net debt | $181.79M | $164.86M | $181.25M | $162.12M | $31.02M |
| Cash flow statement | |||||
| Operating cash flow | $17.73M | $21.57M | -$3.32M | -$21.42M | -$14.30M |
| Capital expenditure | $16.09M | $4.71M | $10.74M | $56.88M | $75.30M |
| Free cash flow | $1.64M | $16.86M | -$14.06M | -$78.30M | -$89.60M |
| Investing cash flow | -$13.22M | -$7.07M | -$6.39M | -$80.86M | -$113.45M |
| Financing cash flow | $767,000 | -$24.46M | $13.87M | $33.98M | $137.66M |
| Depreciation & amortization | $30.99M | $29.89M | $26.59M | $26.49M | $8.41M |
| Stock-based compensation | $2.10M | $4.22M | $8.09M | $23.07M | $14.51M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.